Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-005382-79
    Sponsor's Protocol Code Number:FIL-BBV
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-09-07
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-005382-79
    A.3Full title of the trial
    A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30 + peripheral T-cell lymphoma in first salvage setting: the BBV regimen.
    Studio di fase II con Bendamustina e Brentuximab Vedotin nei linfomi di Hodgkin e linfomi delle cellule T come primo salvataggio: il regime BBV.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase II study with bendamustine plus brentuximab vedotin in Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma in first salvage setting: the BBV regimen.
    Studio di fase II con Bendamustina e Brentuximab Vedotin nei linfomi di Hodgkin e linfomi delle cellule T come primo salvataggio: il regime BBV.
    A.3.2Name or abbreviated title of the trial where available
    FIL-BBV
    FIL-BBV
    A.4.1Sponsor's protocol code numberFIL-BBV
    A.5.4Other Identifiers
    Name:FIL-BBVNumber:FIL-BBV
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorFONDAZIONE ITALIANA LINFOMI ONLUS
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportMillennium Pharma
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportMundipharma
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationFondazione Italiana Linfomi Onlus
    B.5.2Functional name of contact pointUffici Studi FIL
    B.5.3 Address:
    B.5.3.1Street AddressVia del Pozzo, 71
    B.5.3.2Town/ cityModena
    B.5.3.3Post code41121
    B.5.3.4CountryItaly
    B.5.4Telephone number0594222688
    B.5.5Fax number0594223602
    B.5.6E-mailstartup@filinf.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ADCETRIS - 50 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO
    D.2.1.1.2Name of the Marketing Authorisation holderTAKEDA GLOBAL RESEARCH AND DEVELOPMENT CENTRE (EUROPE) LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBrentuximab Vedotin
    D.3.2Product code [IMP1]
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBRENTUXIMAB VEDOTIN
    D.3.9.1CAS number 914088-09-8
    D.3.9.2Current sponsor codeIMP1
    D.3.9.3Other descriptive nameBRENTUXIMAB VEDOTIN
    D.3.9.4EV Substance CodeSUB32397
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name LEVACT - 2.5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE 5 FLACONCINI IN VETRO DA 100 MG
    D.2.1.1.2Name of the Marketing Authorisation holderASTELLAS PHARMA GMBH
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBendamustina
    D.3.2Product code [IMP2]
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBENDAMUSTINA CLORIDRATO
    D.3.9.1CAS number 16506-27-7
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive namebendamustine
    D.3.9.4EV Substance CodeSUB05707MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeagente alchilante
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hodgkin’s lymphoma and CD30+ peripheral T-cell lymphoma
    Linfomi di Hodgkin e linfomi T
    E.1.1.1Medical condition in easily understood language
    Hodgkin’s lymphoma and peripheral T-cell lymphoma
    Linfomi di Hodgkin e linfomi T
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 22.0
    E.1.2Level LLT
    E.1.2Classification code 10012877
    E.1.2Term Diffuse large cell lymphoma (Peripheral T-cell lymphoma unspecified) (Working Formulation) recurrent
    E.1.2System Organ Class 100000004864
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10020328
    E.1.2Term Hodgkin's lymphoma
    E.1.2System Organ Class 100000004864
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To determine the antitumor efficacy, in terms of overall response rate, of bendamustine in combination with brentuximab vedotin in Hodgkin’s lymphoma and CD30+ PTCL as a first salvage treatment.
    • Determinare l’efficacia antitumorale in termini di tasso di risposta globale della Bendamustina in combinazione con Brentuximab Vedotin nei linfomi di Hodgkin e nei linfomi delle cellule T periferiche CD30+ come prima terapia di salvataggio
    E.2.2Secondary objectives of the trial
    To assess the safety and tolerability of the BBV regimen, to evaluate clinical improvement and patients’ survival.
    • Valutare la sicurezza e la tollerabilità del regime BBV
    • Valutare il miglioramento clinico e la sopravvivenza dei pazienti
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    4.1. Inclusion criteria for patients with classical Hodgkin’s lymphoma
    1) Patients at first relapse or with primary refractory disease (i.e. patients who have previously
    received only 1 line of treatment). Patients must have completed any prior treatment with
    radiation, chemotherapy, biologics, immunotherapy and/or other investigational agents at
    least 4 weeks prior to the first BBV dose
    2) Histologically-confirmed CD30+ disease (IHC BerH2 antibody)
    3) Age from 18 to 60 years.
    4) Fluorodeoxyglucose (FDG)-avid and measurable disease (lymph nodes must have long axis
    of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 and short axis > 1.0 cm) as
    documented by both PET and CT.
    5) An Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    6) The following required baseline laboratory data: absolute neutrophil count (ANC) =
    1500/µL, unless known marrow involvement due to disease, platelets = 75,000/µL, unless
    known marrow involvement due to disease, bilirubin = 1.5 x upper limit of normal (ULN) or
    = 3 x ULN for patients with Gilbert’s disease, serum creatinine = 1.5 X ULN, alanine
    aminotransferase (ALT) and aspartate aminotransferase (AST) = 2.5 X ULN.
    7) Serum Albumin = 3 g/dL.
    8) Females of childbearing potential must have a negative serum or urine ß-hCG pregnancy
    test result within 7 days prior to the first dose of therapy. Females of non-childbearing
    potential are those who are postmenopausal for more than 1 year or who have had a bilateral
    tubal ligation or hysterectomy.
    9) Both females of childbearing potential and males who have partners of childbearing
    potential must agree to use an effective contraceptive method during the study and for at
    least 6 months following the last dose of study drug.
    10) Male patients, even if surgically sterilized (i.e., post vasectomy), who:
    •Agree to practice effective barrier contraception during the entire study treatment
    period and through 6 months after the last dose of the study drug, or
    •Agree to completely abstain from heterosexual intercourse
    11) Patients must provide written informed consent.

    4.3. Inclusion criteria for patients with peripheral T-cell lymphomas
    1) Patients with refractory or relapsed PTCL regardless of the number of prior therapy lines.
    Patients must have completed any prior treatment with radiation, chemotherapy, biologics,
    immunotherapy and/or other investigational agents at least 4 weeks prior to the first dose of
    therapy.
    2) Signed written informed consent.
    3) Age from 18 to 60 years.
    4) Histologically confirmed diagnosis of PTCL, i.e. PTCL-not otherwise specified (PTCLNOS),
    angioimmunoblastic T cell lymphoma (AITL) and transformed mycosis fungoides
    according to the World Health Organization (WHO) 2008 classification.
    5) Histologically confirmed CD30+ PTCL (IHC BerH2 antibody).
    6) Eastern Cooperative Oncology Group (ECOG) performance status score of = 1 at study
    entry.
    7) At least one site of measurable disease in two dimensions by computed tomography. Both
    nodal and extranodal sites will be taken into consideration (lymph nodes must have long
    axis of 1.5 cm regardless of short axis or long axis 1.1 to 1.5 cm and short axis > 1.0 cm).
    8) Hematology values within the following limits:
    a. absolute neutrophil count (ANC) = 1500/mm3 independent of growth factor support;
    b. platelets = 75,000/mm3 or = 50,000/mm3 if bone marrow involvement is independent
    of transfusion support;
    c. hemoglobin level = 8 g/dL.
    9) Biochemical values within the following limits:
    a. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x upper
    limit of normal (ULN);
    b. total bilirubin < 1.5 x ULN (unless bilirubin rise is due to Gilbert’s syndrome or has
    a non-hepatic origin);
    c. serum creatinine = 2 x ULN;
    d. serum albumin = 3 g/dL.
    10)Women of childbearing potential must have a negative pregnancy test within 7 days of
    receiving study medication and must agree to use effective contraception, defined as: oral
    contraceptives, double barrier method or practice true abstinence from sexual intercourse
    during the study and for at least 6 months after the last dose of study drug.
    11) Male subjects and their female partners of childbearing potential must be willing to use an
    appropriate method of contraception or practice true abstinence from sexual intercourse
    during the study and for at least 6 months after the last dose of study drug.
    Criteri di inclusione per i pazienti con Linfoma di Hodgkin classico:
    1) Pazienti alla prima recidiva o refrattari ( cioè pazienti che hanno precedentemente eseguito solo una linea di trattamento). I pazienti devono aver completato qualsiasi trattamento precedente con radiazioni, chemioterapia, farmaci biologici, immunoterapia e/o altri agenti sperimentali almeno 4 settimane prima della prima dose di BBV.
    2) Conferma istologica di malattia tramite la positività del marcatore CD30 ( anticorpo IHC BerH2)
    3) Età compresa tra i 18 e i 60 anni inclusi.
    4) Pazienti che abbiano malattia confermata tramite Fluorodesossiglucosio (FDG) e misurabile come documentato dalla PET e dalla CT ( i linfonodi devono avere un asse lungo di 1.5 cm rispetto all’asse corto o un asse lungo da 1.1 a 1.5 e un asse corto > 1.0 cm).
    5) Un ECOG (Eastern Cooperative Oncology Group) performance status di 0 o 1.
    6) Sono richiesti inoltre i seguenti dati di laboratorio: neutrofili assoluti (ANC) =1500/µL, a meno che non ci sia un coinvolgimento noto del midollo dovuto alla malattia, piastrine =75,000/µL, a meno che non ci sia un coinvolgimento noto del midollo dovuto alla malattia, bilirubina =1.5 volte
    superiore al limite normale (ULN) o =3 X ULN per pazienti con malattia di Gilbert, creatinina serica
    =1.5 X ULN, alanina amminotrasferasi (ALT) e aspartato aminotransferasi (AST) =2.5 X ULN.
    7) Albumina serica = 3 g/dL.
    8) Le donne in età fertile dovranno effettuare un test di gravidanza che dovrà risultare ß-hCG negative
    entro 7 giorni prima della prima dose di terapia. Donne non potenzialmente fertili o in menopausa da almeno 1 anno prima della visita di screening o rese chirurgicamente sterili tramite isterectomia o il
    legame bilaterale delle tube.
    9) Le donne in età fertile e gli uomini che hanno partner potenzialmente fertili devono accettare di
    usare metodi contraccettivi efficaci durante lo studio e per almeno 6 mesi dopo l’ultima
    somministrazione del farmaco.
    10) Pazienti di sesso maschile, anche se resi chirurgicamente sterili (stato di post vasectomia) che si impegnano a utilizzare un efficace contraccettivo a barriera durante tutta la durata dello studio e fino a 6 mesi dopo l’ultima somministrazione del farmaco in studio o pazienti di sesso maschile che si impegnano ad astenersi completamente da rapporto eterosessuali.
    11) Pazienti che hanno firmato il consenso informato.

    Criteri di inclusione per i pazienti con linfoma delle cellule T periferiche:
    1) Pazienti con linfoma PTCL recidivato o refrattario indipendentemente dal numero di linee di terapia
    precedenti. I pazienti devono aver completato qualsiasi trattamento precedente con radiazioni,
    chemioterapia, farmaci biologici, immunoterapia e/o altri agenti sperimentali almeno 4 settimane
    prima della prima dose di terapia.
    2) Firma del consenso informato.
    3) Età compresa tra i 18 e i 60 anni inclusi.
    4) Conferma istologica di PTCL, cioè PTCL non altrimenti specificato (PTCL-NOS), linfoma
    angioimmunoblastico a cellule T (AITL), e micosi fungoidi trasformate secondo la classificazione
    WHO 2008.
    5) PTCL confermato istologicamente come CD30 positivo (anticorpo IHC BerH2).
    6) Performance status ECOG = 1 all’arruolamento.
    7) Almeno un sito di malattia misurabile bidimensionalmente tramite esame di tomografia
    computerizzata assiale (TAC). Verrà presa in considerazione sia malattia nodale sia extranodale (i linfonodi devono avere l’asse maggiore di 1.5 cm indipendentemente dalla lunghezza dell’asse
    minore oppure l’asse maggiore di una lunghezza compresa tra 1.1 e 1.5 cm e il minore >1.0 cm).
    8) I valori ematologici devono essere nei seguenti limiti:
    o Conta assoluta dei neutrofili = 1500 /mm3 senza supporto di fattori di crescita;
    o Piastrine = 75,000/mm3 o = 50,000/mm3 se il coinvolgimento midollare è indipendente dal
    supporto trasfusionale;
    o Emoglobina = 8 gr/dL.
    9) I valori biochimici devono essere nei seguenti limiti:
    o Alanina aminotransferasi (ALT) e aspartato aminotransferasi (AST) < 3 volte il limite superiore
    del valore normale (ULN);
    o Bilirubina totale < 1.5 x ULN (a meno che l’aumento di bilirubina non sia dovuta alla sindrome di Gilbert o comunque di origine non epatica);
    o Cretinina sierica = 2 x ULN;
    o Albumina sierica = 3 gr/dL.
    10) Le donne fertili devono avere un test di gravidanza negativo entro la settimana precedente la prima somministrazione dei farmaci in studio e devono accettare di utilizzare un contraccettivo efficace definito come: contraccettivo orale, metodo di doppia barriera o praticare astinenza da rapporti
    sessuali durante lo studio e per 6 mesi dall’ultima dose della terapia.
    11) I soggetti maschili e le loro compagne fertili devono accettare di utilizzare un appropriato metodo contraccettivo o praticare l’astinenza da rapporti sessuali durante lo studio e per 6 mesi dopo l’ultima dose della terapia.
    E.4Principal exclusion criteria
    4.2. Exclusion criteria for patients with classical Hodgkin’s lymphoma
    1) Previous treatment with bendamustine or brentuximab vedotin.
    2) Prior autologous stem cell transplant.
    3) Known history of any of the following cardiovascular conditions: myocardial infarction
    within 2 years of study entry; NYHA class III or IV heart failure; cardiac arrhythmias;
    angina; any electrocardiographic evidence of acute ischemia or conduction system
    abnormalities; recent evidence (within 6 months before the first dose of study drug) of a leftventricular ejection fraction < 50%.
    4) History of another primary malignancy for within 3 years of study entry (the following are
    exempt from the 3-year limit: non-melanoma skin cancer, curatively treated localized
    prostate cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion
    on PAP smear).
    5) Known cerebral/meningeal disease (HL or any other etiology) or testicular involvement.
    6) Signs or symptoms of progressive multifocal leukoencephalopathy (PML).
    7) Pre-existing Peripheral Neuropathy = 2.
    8) Any active systemic viral, bacterial, or fungal infection requiring treatment with
    antimicrobial therapy within 2 weeks prior to the first dose of therapy.
    9) Current therapy with other systemic anti-neoplastic or investigational agents.
    10) Therapy with corticosteroids at greater than or equal to 20 mg/day prednisone equivalent
    within 1 week prior to the first dose of therapy.
    11)Women who are pregnant or breastfeeding.
    12) Patients with a known hypersensitivity to recombinant proteins, murine proteins, or any
    excipient contained in the drug formulation of brentuximab vedotin and to bendamustine.
    13)Known human immunodeficiency virus (HIV) positivity.
    14)Known hepatitis B surface antigen (HBsAg) positivity or known or suspected active
    hepatitis C infection.
    15) Patients with dementia or altered mental state that would preclude the understanding and
    rendering of informed consent.

    4.4. Exclusion criteria for patients with peripheral T-cell lymphomas
    1) Diagnosis of cutaneous T-cell lymphoma, anaplastic large-cell lymphoma (ALCL), mycosis
    fungoides or Sézary Syndrome.
    2) Previous treatment with bendamustine or brentuximab vedotin.
    3) Prior autologous stem cell transplant.
    4) Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient
    contained in the drug formulation of brentuximab vedotin and to bendamustine.
    5) Any serious active disease or co-morbid medical condition (according to investigator's
    decision).
    6) Prior history of malignancies other than lymphoma (except for a history of a complete
    resection for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the
    cervix or breast) unless the subject has been free of the disease for = 3 years.
    7) Pre-existing peripheral neuropathy grade = 2.
    8) Signs or symptoms of progressive multifocal leukoencephalopathy (PML).
    9) Any serious medical condition, laboratory abnormality, or psychiatric illness that would
    prevent the subject from signing the informed consent form.
    10) Pregnant or lactating females or men or women of childbearing potential not willing to use
    an adequate method of birth control for the duration of the study or a positive pregnancy test
    on day 1 before first dose of study drug.
    11) Central nervous system disease (meningeal and/or brain involvement by lymphoma) or
    testicular involvement.
    12)History of clinically relevant liver or renal insufficiency; significant pulmonary,
    gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or
    metabolic disturbances.
    13)Known history of any of the following cardiovascular conditions: myocardial infarction
    within 2 years of study entry; NYHA class III or IV heart failure; cardiac arrhythmias;
    angina; any electrocardiographic evidence of acute ischemia or conduction system
    abnormalities; recent evidence (within 6 months before the first dose of study drug) of a leftventricular
    ejection fraction < 50%.
    14)Active systemic, viral, bacterial, or fungal infection requiring systemic antibiotics within 2
    weeks prior to first dose of study drug.
    15)Known human immunodeficiency virus (HIV) positivity.
    16)Known hepatitis B surface antigen (HBsAg) positivity or known or suspected active
    hepatitis C infection.
    17) Prior allogeneic stem cell transplant
    18) Patients with dementia or altered mental state that would preclude the understanding and
    rendering of informed consent.
    Criteri di esclusione per i pazienti con Linfoma di Hodgkin classico:
    1) Precedente trattamento con Bendamustina o Brentuximab Vedotin.
    2) Precedente trapianto autologo di cellule staminali.
    3) Storia conosciuta di una delle seguenti condizioni cardiovascolari: infarto del miocardio nei 2 anni precedenti l’entrata in studio; insufficienza cardiaca di classe III o IV secondo la classificazione New York Heart Association (NYHA); evidenza di condizioni cardiovascolari non controllate incluse aritmie cardiache, angina o evidenza elettrocardiografica di ischemia acuta o anomalie attive del sistema di conduzione; recenti evidenze (entro 6 mesi dalla somministrazione della prima dose del farmaco in studio) di una frazione di eiezione ventricolare sinistra <50%
    4) Altra neoplasia diagnosticata o trattata nei 3 anni precedenti l’inizio della terapia Non vengono
    esclusi i pazienti con tumori della pelle (non melanoma), carcinoma della prostata localizzato trattato per la cura e carcinoma della cervice in situ sottoposti a resezione completa o carcinoma squamoso intraepiteliale valutato con il PAP test.
    5) I pazienti con nota malattia cerebrale/meningea (HL o qualsiasi altra eziologia) o coinvolgimento
    testicolare
    6) I pazienti con segni o sintomi di leucoencefalopatia multifocale progressiva (PML).
    7) Neuropatia periferica pre esistente = 2.
    8) Pazienti con infezione virale, batterica o fungina attiva che richiede un trattamento con terapia
    antibiotica entro 2 settimane precedenti alla prima dose di terapia.
    9) I pazienti che stanno facendo terapia con agenti sistemici antineoplastici o altri agenti sperimentali.
    10) Pazienti che hanno fatto terapia con corticosteroidi in misura = 20 mg/die (per esempio prednisone) entro una settimana prima dell’inizio della terapia.
    11) Donne in gravidanza o allattamento
    12) Pazienti con nota ipersensibilità alle proteine ricombinanti, alle proteine murine o ad un qualsiasi
    eccipiente contenuto nella formulazione farmacologica del Brentuximab Vedotin e alla
    Bendamustina
    13) Pazienti HIV positivi
    14) Epatite B nota HBsAg + o sospetta o conosciuta infezione da epatite C attiva.
    15) Pazienti con una demenza o un alterato stato mentale che precluderebbe la reale comprensione e rilascio del consenso informato.

    Criteri di esclusione per i pazienti con linfoma delle cellule T periferiche:
    1) Diagnosi di CTCL, ALCL, micosi fungoide o sindrome di Sezary;
    2) Precedente trattamento con Bendamustina o Brentuximab Vedotin.
    3) Precedente trapianto autologo di cellule staminali.
    4) Pazienti con nota ipersensibilità alle proteine ricombinate, alle proteine murine o ad un qualsiasi
    eccipiente contenuto nella formulazione farmacologica del Brentuximab Vedotin e alla
    bendamustina.
    5) Qualsiasi malattia o co-morbidità attiva seria (a discrezione dello Sperimentatore)
    6) Precedente storia di neoplasie diverse dal linfoma (ad eccezione di carcinoma basocellulare o
    squamoso della cute o carcinoma in situ della cervice o della mammella) a meno che il soggetto non sia indenne da questa malattia da almeno 3 anni.
    7) Pazienti con neuropatia periferica di grado = 2.
    8) Segni o sintomi di leucoencefalopatia multifocale progressiva
    9) Pazienti con una demenza o un alterato stato mentale o condizione medica che precluderebbe la reale comprensione e rilascio del consenso informato.
    10) Donne in gravidanza o in allattamento o uomini e donne potenzialmente fertili che non sono disposti ad utilizzare un metodo adeguato di controllo delle nascite per tutta la durata dello studio o donne il cui test di gravidanza eseguito al giorno 1 del trattamento risulti positivo.
    11) Malattie del SNC (meningea e / o coinvolgimento del cervello da linfoma) o coinvolgimento testicolare.
    12) Storia di insufficienza epatica o renale clinicamente rilevante; disturbi significativi polmonari, gastrointestinali, endocrini, neurologici, reumatologici, ematologici, psichiatrici o metabolici.
    13) Anamnesi positiva per una delle seguenti condizioni cardiovascolari:
    infarto del miocardio entro 2 anni dall’arruolamento nello studio
    - Insufficienza cardiaca di Classe III o IV in accordo con New York Heart Association(NYHA)
    - Evidenza di patologie cardiovascolari non controllate, comprese le aritmie cardiache,
    insufficienza cardiaca congestizia (CHF), angina pectoris, o prova elettrocardiografica di
    ischemia acuta o di anomalie attive del sistema di conduzione cardiaca;
    - Evidenza di una frazione di eiezione ventricolare sinistra <50% (esame effettuato entro 6 mesi
    dalla prima dose del farmaco sperimentale)
    14) Pazienti con infezione virale, batterica o fungina attiva che richiede un trattamento con terapia
    antibiotica entro 2 settimane precedenti alla prima dose di terapia
    15) Positivita nota al virus dell’HIV
    16) Epatite B nota HBsAg + o sospetta infezione da epatite C attiva.
    17) Precedente trapianto allogenico di cellule staminali.
    18) Pazienti con una demenza o un alterato stato mentale che precluderebbe la reale comprensione e rilascio d
    E.5 End points
    E.5.1Primary end point(s)
    overall objective response rate (ORR).
    Tasso di risposta generale (ORR).
    E.5.1.1Timepoint(s) of evaluation of this end point
    6 months
    6 mesi
    E.5.2Secondary end point(s)
    the complete remission (CR) rate; the progression-free survival (PFS) and overall survival (OS) ; the type, incidence, severity, seriousness, of adverse events and laboratory abnormalities observed during treatment and the assessment of any potential relationship to the study drugs.; the duration of the response (DOR);
    Tasso di remissioni complete (CR) ; Sopravvivenza libera da progressione (PFS) e sopravvivenza (OS; Il tipo, l’incidenza, la gravità, la serietà degli eventi avversi e le anomalie laboratoristiche osservate durante il trattamento e la valutazione di qualsiasi potenziale relazione con i farmaci in studio; Durata della risposta (DOR)
    E.5.2.1Timepoint(s) of evaluation of this end point
    6 months; 1 year; 54 months; 4
    6 mesi; 1 anno; 54 mesi; 4
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Studio clinico a braccio singolo multicentrico in aperto di fase II
    single-arm, open-label, multicenter, phase 2 clinical trial
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months6
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 65
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state65
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 65
    F.4.2.2In the whole clinical trial 65
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    nd
    na
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-09-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-09-15
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:27:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA